Table 1 Patient demographics and baseline disease characteristics
Characteristic | US commercial cetuximab Arm A (N = 77) | BI-manufactured cetuximab Arm B (N = 71) |
|---|---|---|
Sex, n (%) | ||
Male | 68 (88.3) | 55 (77.5) |
Age, years | ||
Median (range) | 57.8 (26.9–77.2) | 61.3 (29.2–81.9) |
KPS score, n (%) | ||
70 | 9 (11.7) | 7 (9.9) |
80 | 28 (36.4) | 22 (31.0) |
90 | 32 (41.6) | 31 (43.7) |
100 | 8 (10.4) | 11 (15.5) |
Stage of disease, n (%) | ||
Local | 8 (10.4) | 12 (16.9) |
Locoregional | 26 (33.8) | 20 (28.2) |
Metastatic | 43 (55.8) | 38 (53.5) |
Histologic type, n (%) | ||
Well differentiated | 3 (3.9) | 6 (8.5) |
Moderately differentiated | 35 (45.5) | 29 (40.8) |
Poorly differentiated | 25 (32.5) | 17 (23.9) |
Undifferentiated | 3 (3.9) | 1 (1.4) |
Unable to determine | 11 (14.3) | 15 (21.1) |
Missing/unknown | 0 | 2 (2.8) |